The Covid continues to drive BioNTech's financial results.
The pandemic, which suddenly brought the young German company from the shadows to the light, will allow it to generate 16 to 17 billion euros in revenue in 2021. With its powerful ally Pfizer, it will have delivered this year 2, 5 billion vaccines against Covid in 152 countries.
An exceptional opportunity for the company, which had never marketed a product before the Covid-19.
To read also
“Pfizergate”: is the anti-Covid vaccine from the American laboratory at the heart of a health scandal?
In the third quarter, the two laboratories continued their commercial offensive.
They thus concluded the sale of 50 million doses intended for 5-12 year olds in the United States (i.e. 600 million doses in total purchased by the American government) and 120 million doses in Japan (314 million in total). .
"Our robust, regulatory and clinical strategy has enabled us to obtain several approvals over the recent period which broaden the access of our vaccine to other categories of the population"
, welcomed
This article is for subscribers only.
You have 73% left to discover.
To cultivate your freedom is to cultivate your curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
